French pharma giant shaping global healthcare
The NHS in England and Wales has approved teplizumab, the first drug that can delay onset of type 1 diabetes. The immunotherapy offers up to three extra years before symptoms require lifelong insulin, with rollout backed by NICE and a commercial deal with Sanofi.
The FDA has approved Lipfendra, Merck’s oral PCSK9 inhibitor, to lower LDL cholesterol in patients on statins. Trials show ~55-60% LDL reductions; the pill will be sold at about $315/month and must be taken on an empty stomach. Analysts see potential peak sales in the billions as injectable rivals face competition and access barriers.